Jonathan Violin - 01 Feb 2022 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role: Chief Executive Officer, Director
Signature: /s/ Lara Meisner, Attorney-in-Fact for Jonathan Violin
Issuer symbol: VRDN
Transactions as of: 01 Feb 2022
Net transactions value: -$572,818
Form type: 4
Filing time: 03 Feb 2022, 17:11:27 UTC
Previous filing: 10 Dec 2021
Next filing: 03 Mar 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VRDN	Common Stock	Sale	$327,482	-16,751	-2.7%	$19.55	614,154	01 Feb 2022	Direct	F1
transaction	VRDN	Common Stock	Sale	$227,920	-12,340	-2%	$18.47	601,814	02 Feb 2022	Direct	F2
transaction	VRDN	Common Stock	Sale	$17,416	-909	-0.15%	$19.16	600,905	03 Feb 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VRDN	Stock Option (Right to Buy)	Award	$0	+280,000		$0.000000	280,000	02 Feb 2022	Common Stock	280,000	$18.51	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.90 to $20.23. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2	This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.32 to $19.49. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3	This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $18.04 to $19.66. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F4	The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.